Docosahexaenoic acid and hydroxytyrosol co-administration fully prevents liver steatosis and related parameters in mice subjected to high-fat diet: A molecular approach.
Animals
Diet, High-Fat
/ adverse effects
Dietary Supplements
Disease Models, Animal
Docosahexaenoic Acids
/ pharmacology
Drug Synergism
Fatty Liver
/ diet therapy
Humans
Inflammation
/ diet therapy
Lipid Metabolism
/ drug effects
Liver
/ drug effects
Mice
Oxidative Stress
/ drug effects
PPAR alpha
/ genetics
Phenylethyl Alcohol
/ analogs & derivatives
docosahexaenoic acid
hydroxytyrosol
liver steatosis
oxidative stress
pro-inflammatory status
Journal
BioFactors (Oxford, England)
ISSN: 1872-8081
Titre abrégé: Biofactors
Pays: Netherlands
ID NLM: 8807441
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
28
06
2019
accepted:
01
08
2019
pubmed:
28
8
2019
medline:
18
4
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Attenuation of high-fat diet (HFD)-induced liver steatosis is accomplished by different nutritional interventions. Considering that the n-3 PUFA docosahexaenoic acid (DHA) modulates lipid metabolism and the antioxidant hydroxytyrosol (HT) diminishes oxidative stress underlying fatty liver, it is hypothesized that HFD-induced steatosis is suppressed by DHA and HT co-administration. Male C57BL/6J mice were fed a control diet (CD; 10% fat, 20% protein, 70% carbohydrates) or a HFD (60% fat, 20% protein, 20% carbohydrates) for 12 weeks, without and with supplementation of DHA (50 mg/kg/day), HT (5 mg/kg/day) or both. The combined DHA + HT protocol fully prevented liver steatosis and the concomitant pro-inflammatory state induced by HFD, with suppression of lipogenic and oxidative stress signaling, recovery of fatty acid oxidation capacity and enhancement in resolvin availability affording higher inflammation resolution capability. Abrogation of HFD-induced hepatic steatosis by DHA and HT co-administration represents a crucial therapeutic strategy eluding disease progression into stages lacking efficacious handling at present time.
Substances chimiques
PPAR alpha
0
3,4-dihydroxyphenylethanol
10597-60-1
Docosahexaenoic Acids
25167-62-8
Phenylethyl Alcohol
ML9LGA7468
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
930-943Subventions
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 11140174
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1181774
Informations de copyright
© 2019 International Union of Biochemistry and Molecular Biology.
Références
Angulo P. Nonalcoholic fatty liver disease. New England J. Med. 2002;346:1221-1231.
Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349-360.
McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. J Hepatol. 2015;62:1148-1155.
Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on nonalcoholic fatty liver disease: An overview of present and future therapies. J Clin Transl Hepatol. 2017;5:67-75.
Caldwell S. NASH therapy: Omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. Clin Mol Hepatol. 2017;23:103-108.
Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24:3361-3373.
Valenzuela R, Videla LA. Crosstalk mechanisms in hepatoprotection: Thyroid hormone-docosahexaenoic acid (DHA) and DHA-extra virgin olive oil combined protocols. Pharmacol Res. 2018;132:168-175.
Mardones M, Valenzuela R, Romanque P, et al. Prevention of liver ischemia reperfusion injury by a combined thyroid hormone and fish oil protocol. J Nutr Biochem. 2012;23:1113-1120.
Valenzuela R, Espinosa A, Llanos P, et al. Anti-steatotic effects of an n-3 LCPUFA and extra virgin olive oil mixture in the liver of mice subjected to high-fat diet. Food Funct. 2016;7:140-150.
Echeverría F, Valenzuela R, Bustamante A, et al. Attenuation of high-fat diet-induced rat liver oxidative stress and steatosis by combined hydroxytyrosol- (HT-) eicosapentaenoic acid supplementation mainly relies on HT. Oxid Med Cell Longev. 2018;2018:5109503.
Echeverría F, Valenzuela R, Espinosa A, et al. Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: Involvement of resolvins RvE1/2 and RvD1/2. J Nutr Biochem. 2019;63:35-43.
Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol. 2008;8:349-361.
Depner CM, Traber MG, Bobe G, et al. A Metabolomic analysis of Omega-3 fatty acid-mediated attenuation of Western diet-induced nonalcoholic Steatohepatitis in LDLR-/- mice. PLoS One. 2013;8:e83756.
Song J, Li C, Lv Y, Zhang Y, Amakye WK, Mao L. DHA increases adiponectin expression more effectively than EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in 3T3-L1 adipocytes. Nutr Metab. 2017;14:52.
Calder PC. Docosahexaenoic Acid. Ann Nutr Metab. 2016;69:8-21.
Valenzuela R, Barrera C, Espinosa A, Llanos P, Orellana P, Videla LA. Reduction in the desaturation capacity of the liver in mice subjected to high fat diet: Relation to LCPUFA depletion in liver and extrahepatic tissues. Prostaglandins Leukot Essent Fatty Acids. 2015;98:7-14.
Valenzuela R, Ortiz M, Hernández-Rodas MC, Echeverría F, Videla LA. Targeting n-3 polyunsaturated fatty acids in non-alcoholic fatty liver disease. Curr Med Chem. 2019;26:1-22. https://doi.org/10.2174/0929867326666190410121716.
Schuck RN, Zha W, Edin ML, et al. The cytochrome P450 Epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One. 2014;9:e110162.
Gao L, Wang J, Sekhar KR, et al. Noveln-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem. 2007;282:2529-2537.
Piro S, Spadaro L, Russello M, et al. Molecular determinants of insulin resistance, cell apoptosis and lipid accumulation in non-alcoholic steatohepatitis. Nutr Metab Cardiovasc Dis. 2008;18:545-552.
Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
Rahman I, Kode A, Biswas S. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc. 2006;1:3153.
Zimmermann R, Haemmerle G, Wagner EM, Strauss JG, Kratky D, Zechner R. Decreased fatty acid esterification compensates for the reduced lipolytic activity in hormone-sensitive lipase-deficient white adipose tissue. J Lipid Res. 2003;44:2089-2099.
Halestrap AP, Denton RM. Insulin and the regulation of adipose-tissue acetyl-coenzyme a carboxylase. Biochem J. 1973;132:509-517.
Karlic H, Lohninger S, Koeck T, Lohninger A. Dietary L-carnitine stimulates Carnitine Acyltransferases in the liver of aged rats. J Histochem Cytochem. 2002;50:205-212.
Vamecq J. Fluorometric assay of peroxisomal oxidases. Anal Biochem. 1990;186:340-349.
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158.
Horn H. Glutathione Reductase. In: Bergmeyer H, editor. Methods of enzymatic assays. New York: Academic Press, 1965; p. 875.
Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130.
Satomura S, Miki Y, Hamanaka T, Sakata Y. Kinetic assay of gamma-glutamyltransferase with use of bilirubin oxidase as a coupled enzyme. Clin Chem. 1985;31:1380.
Lück H. Catalase. In: Bergmeyer H, editor. Methods of enzymatic assays. New York: Academic Press, 1965; p. 885.
Ernster L, Navazio F, Löw H, Siekevitz P, Ernster L, Diczfalusy E. Soluble Diaphorase in animal tissues. Acta Chem Scand. 1958;12:595.
Shimano H, Sato R. SREBP-regulated lipid metabolism: Convergent physiology - Divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710-730.
Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-1131.
Rincón-Cervera MA, Valenzuela R, Hernandez-Rodas MC, et al. Supplementation with antioxidant-rich extra virgin olive oil prevents hepatic oxidative stress and reduction of desaturation capacity in mice fed a high-fat diet: Effects on fatty acid composition in liver and extrahepatic tissues. Nutrition. 2016;32:1254-1267.
Ferré P, Foufelle F. SREBP-1c transcription factor and lipid homeostasis: Clinical perspective. Horm Res. 2007;68:72-82.
Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res. 2016;57:1329-1338.
Videla LA, Rodrigo R, Orellana M, et al. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci. 2004;106:261-268.
Araya J, Rodrigo R, Videla LA, et al. Increase in long-chain polyunsaturated fatty acid n−6/n−3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci. 2004;106:635-643.
Gentile CL, Frye MA, Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors. 2011;37:8-16.
Zheng Z, Zhang C, Zhang K. Role of unfolded protein response in lipogenesis. World J Hepatol. 2010;2:203.
Niture SK, Kaspar JW, Chen J, Jaiswal AK. Nrf2 signaling and cell survival. Toxicol Appl Pharmacol. 2010;244:37-42.
Illesca P, Valenzuela R, Espinosa A, et al. Hydroxytyrosol supplementation ameliorates the metabolic disturbances in white adipose tissue from mice fed a high-fat diet through recovery of transcription factors Nrf2, SREBP-1c, PPAR-γ and NF-κB. Biomed Pharmacother. 2019;109:2472-2481.
Videla LA. Combined docosahexaenoic acid and thyroid hormone supplementation as a protocol supporting energy supply to precondition and afford protection against metabolic stress situations. IUBMB Life. 2019;71:1211-1220. https://doi.org/10.1002/iub.2067.
Araya J, Rodrigo R, Pettinelli P, Araya AV, Poniachik J, Videla LA. Decreased liver fatty acid Δ-6 and Δ-5 Desaturase activity in obese patients. Obesity. 2010;18:1460-1463.
Nakamura MT, Nara TY. Gene regulation of mammalian desaturases. Biochem Soc Trans. 2002;30:1076-1079.
Iacobazzi V, Infantino V, Palmieri F. Transcriptional regulation of the mitochondrial citrate and Carnitine/Acylcarnitine transporters: Two genes involved in fatty acid biosynthesis and β-oxidation. Biology. 2013;2:284-303.
Deng X, Dong Q, Bridges D, Raghow R, Park EA, Elam MB. Docosahexaenoic acid inhibits proteolytic processing of sterol regulatory element-binding protein-1c (SREBP-1c) via activation of AMP-activated kinase. Biochim Biophys Acta. 2015;1851:1521-1529.
Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications-a review. Nutr J. 2014;13:1.
Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol. 2011;54:795-809.
Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: More than just another fat cell hormone? Diabetes Care. 2003;26:2442-2450.
Echeverría F, Ortiz M, Valenzuela R, Videla LA. Hydroxytyrosol and Cytoprotection: A projection for clinical interventions. Int J Mol Sci. 2017;18:930.
Peyrol J, Riva C, Amiot MJ. Hydroxytyrosol in the prevention of the metabolic syndrome and related disorders. Nutrients. 2017;9:306.
Valenzuela R, Echeverría F, Ortiz M, et al. Hydroxytyrosol prevents reduction in liver activity of Δ-5 and Δ-6 desaturases, oxidative stress, and depletion in long chain polyunsaturated fatty acid content in different tissues of high-fat diet fed mice. Lipids Health Dis. 2017;16:64.
Cao K, Xua J, Zou X, et al. Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. Biol Med. 2014;67:396.
Echeverría F, Ortiz M, Valenzuela R, Videla LA. Long-chain polyunsaturated fatty acids regulation of PPARs, signaling: Relationship to tissue development and aging. Prostaglandins Leukot Essent Fatty Acids. 2016;114:28-34.
Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest. 2008;118:3160-3169.
Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 2005;115:1298-1305.
Batetta B, Griinari M, Carta G, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr. 2009;139:1495-1501.
Demizieux L, Piscitelli F, Troy-Fioramonti S, et al. Early low-fat diet enriched with Linolenic acid reduces liver Endocannabinoid tone and improves late glycemic control after a high-fat diet challenge in mice. Diabetes. 2016;65:1824-1837.
Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol. 2013;34:446-452.
Videla LA. Liver NF-κB and AP-1 activation and PPAR-α expression are negatively correlated in obese patients: Pro-inflammatory implications. Clin Nutr. 2010;29:687-688.
Williams-Bey Y, Boularan C, Vural A, et al. Omega-3 free fatty acids suppress macrophage Inflammasome activation by inhibiting NF-κB activation and enhancing autophagy. PLoS One. 2014;9:e97957.
Sui YH, Luo WJ, Xu QY, Hua J. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. World J Gastroenterol. 2016;22:2533-2544.
Martínez-Micaelo N, González-Abuín N, Pinent M, Ardévol A, Blay M. Dietary fatty acid composition is sensed by the NLRP3 inflammasome: Omega-3 fatty acid (DHA) prevents NLRP3 activation in human macrophages. Food Funct. 2016;7:3480-3487.
Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an Omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687-698.
Pirozzi C, Lama A, Simeoli R, et al. Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD. J Nutr Biochem. 2016;30:108-115.
Killeen MJ, Linder M, Pontoniere P, Crea R. NF-κβ signaling and chronic inflammatory diseases: Exploring the potential of natural products to drive new therapeutic opportunities. Drug Discov Today. 2014;19:373-378.
Kohli P, Levy BD. Resolvins and protectins: Mediating solutions to inflammation. Br J Pharmacol. 2009;158:960-971.
Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev. 2018;2018:9547613.
Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2019;16:377-386.